News

GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.

Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c

Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.

Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.

The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect

Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".

The company said it reached an agreement with firms representing plaintiffs in the outstanding talc cases to pay up to $3 billion in claim payments in 2027, with no further payments due before 2028.

Shares of Legend Biotech fell 14% Monday after the company announced that CEO Ying Huang stepped down and left the board. Legend said in a regulatory filing that Huang’s resignation was not the result of a disagreement with the company, but didn’t say anything more about why he left. Huang said he was departing the company to work with a venture fund focusing on drug development.

Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]

Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.

A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.

Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.

July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.

All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led

A series of big bank results kicked off the second quarter earnings season on Tuesday.

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.

Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the memory chip trade — particularly the intraday performances of Micron Technology (MU), SK Hynix (000660.KS), and Samsung (005930.KS) — as these three big names have seemingly dragged the sector into a bear market.

Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the memory chip trade — particularly the intraday performances of Micron Technology (MU), SK Hynix (000660.KS), and Samsung (005930.KS) — as these three big names have seemingly dragged the sector into a bear market.

US markets are set for a mixed open on Tuesday, with technology stocks expected to come under pressure after Samsung delivered record quarterly profits that still failed to satisfy investors, raising fresh questions about AI valuations. Nasdaq futures were down 1.1% ahead of the opening bell,...

7.47am: Shell gives pre-results update Shell says stronger trading in its integrated gas business and improved refining margins should support second-quarter performance, although production has been hit by disruption to output from Qatar following the Iran war. Ahead of second-quarter...

US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).

While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.

Johnson & Johnson (NYSE:JNJ) is included among the Dividend Stock Portfolio: Top 10 Stocks to Buy According to Reddit. On May 31, Reuters reported that Johnson & Johnson (NYSE:JNJ)’s prostate cancer drug Erleada, when used alongside hormone-blocking therapy for six months before and after prostate surgery, improved the chances of eliminating cancer and lowered the […]

Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. Now it wants to show it can keep doing that for years. On June 13, the company reported results from a late-stage trial of its blood-cancer drug TALVEY, and the data landed at one of the year's ...